Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.470
+0.010 (0.68%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Pliant Therapeutics Stock Forecast
PLRX's stock price has decreased by -87.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 9.79, with a low estimate of 1.50 and a high estimate of 45. The average target predicts an increase of 565.99% from the current stock price of 1.47.
Analyst Consensus: Hold
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for Pliant Therapeutics stock from 10 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 0 | 0 |
| Buy | 4 | 4 | 4 | 3 | 1 | 1 |
| Hold | 0 | 0 | 0 | 6 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 4, 2025 |
| Citigroup | Citigroup | Hold Maintains $4 → $1.5 | Hold | Maintains | $4 → $1.5 | +2.04% | Mar 4, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +104.08% | Mar 4, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 4, 2025 |
Financial Forecast
Revenue This Year
3.57M
Revenue Next Year
2.04M
from 3.57M
Decreased by -42.86%
EPS This Year
-2.34
from -3.47
EPS Next Year
-2.03
from -2.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 51.2M | ||
| Avg | 3.6M | 2.0M | 9.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 488.2% | 2,411.3% | ||
| Avg | - | -42.9% | 355.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.53 | -0.96 | -0.57 | ||
| Avg | -2.34 | -2.03 | -1.51 | ||
| Low | -3.07 | -2.66 | -3.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.